Dr. Jim Wei, formerly a senior reviewer at the USFDA, was recently interviewed by Interfax on his insights into US generic drug market opportunities that are present to Chinese pharmaceutical companies.

According to Wei, the FDA is in the process of trying to reduce drug prices for U.S. consumers, and offer them access to good quality drugs while avoiding hurting innovative drug developers' interests.

------------------------------------------------------------------------------------

This is not an article published by Pharma China, and please visit the following website link for the full text of the article.  The availability of the article is under the control of its publisher.  We may keep a copy of the article offline, so subscribers who can not access the article online can contact info@pharmachinaonline.com for further information.

http://www.interfax.cn/news/2586/

Note: By clicking on the above link, you will leave Pharma China Online. If you wish to return to this website, please click on "Back" button or log onto Pharma China Online again.